{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:02:55Z","timestamp":1772805775056,"version":"3.50.1"},"reference-count":11,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,4,15]],"date-time":"2013-04-15T00:00:00Z","timestamp":1365984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cutan Pathol"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:p>Vemurafenib is an inhibitor of BRAF and is used to treat patients with metastatic melanoma who carry a V600E BRAF mutation.  Recently, four patients have been described in the literature who developed a neutrophilic panniculitis following treatment with a BRAF inhibitor.  We present an additional case and review the clinical findings of the cases reported to date.<\/jats:p>","DOI":"10.1111\/cup.12149","type":"journal-article","created":{"date-parts":[[2013,4,15]],"date-time":"2013-04-15T07:10:47Z","timestamp":1366009847000},"page":"667-669","source":"Crossref","is-referenced-by-count":33,"title":["Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib"],"prefix":"10.1111","volume":"40","author":[{"given":"Gene H.","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Dermatology University of Southern California  Los Angeles CA USA"},{"name":"Department of Pathology University of Southern California  Los Angeles CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Levy","sequence":"additional","affiliation":[{"name":"Levy Dermatology  Memphis TN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goli","family":"Compoginis","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Southern California  Los Angeles CA USA"},{"name":"Levy Dermatology  Memphis TN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,4,15]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.226"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2012.00975.x"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002011"},{"issue":"15","key":"e_1_2_4_6_1","article-title":"Phase I\/II study of GSK2118436, a selective inhibitory of oncogenic mutant BRAF kinase, in patients with metastatic melanoma an other solid tumors [abstract 8503]","volume":"28","author":"Kefford R","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_4_7_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.15_suppl.8509","article-title":"Brim\u20102: an open\u2010label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation\u2010positive metastatic melanoma [abstract 8509]","volume":"29","author":"Ribas A","year":"2011","journal-title":"J Clin Oncol"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.2842"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e3283570792"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.08.011"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2008.01019.x"},{"key":"e_1_2_4_12_1","first-page":"503","article-title":"Sweet's syndrome associated with granulocyte colony\u2010stimulating factor","volume":"8","author":"Hasegawa M","year":"1988","journal-title":"Eur J Dermatol"}],"container-title":["Journal of Cutaneous Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcup.12149","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cup.12149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T18:17:31Z","timestamp":1700677051000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cup.12149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,15]]},"references-count":11,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1111\/cup.12149"],"URL":"https:\/\/doi.org\/10.1111\/cup.12149","archive":["Portico"],"relation":{},"ISSN":["0303-6987","1600-0560"],"issn-type":[{"value":"0303-6987","type":"print"},{"value":"1600-0560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,15]]}}}